| Q93112456 | A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments |
| Q91593185 | A Systematic Review of Methods to Predict Weight Trajectories in Health Economic Models of Behavioral Weight-Management Programs: The Potential Role of Psychosocial Factors |
| Q82954086 | A cost per live birth comparison of HMG and rFSH randomized trials |
| Q30244099 | A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure |
| Q37363366 | A system analysis of a suboptimal surgical experience |
| Q38212591 | A systematic and critical review of model-based economic evaluations of pharmacotherapeutics in patients with bipolar disorder |
| Q47973287 | A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. |
| Q38827607 | A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. |
| Q28072735 | A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems |
| Q64117727 | A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions |
| Q92007155 | Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review |
| Q38074889 | Acknowledging patient heterogeneity in economic evaluation : a systematic literature review. |
| Q40160107 | An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting. |
| Q58765273 | Application of discrete event simulation in health care: a systematic review |
| Q52901487 | Aspects of health economic evaluations as a contribution to the priority-setting debate in Germany |
| Q51612407 | Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. |
| Q33449026 | At-risk adolescents as experts in a new requirements elicitation procedure for the development of a smart phone psychoeducational trauma-informed care application |
| Q38632641 | Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. |
| Q28603996 | Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment |
| Q38766423 | Calibrating Parameters for Microsimulation Disease Models: A Review and Comparison of Different Goodness-of-Fit Criteria |
| Q35568861 | Can discrete event simulation be of use in modelling major depression? |
| Q36871294 | Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions |
| Q34108081 | Chronic disease modeling and simulation software |
| Q44413969 | Comparing three software tools for implementing markov models for health economic evaluations |
| Q27335069 | Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party |
| Q49054829 | Continuous time simulation and discretized models for cost-effectiveness analysis |
| Q34732890 | Cost effectiveness of patient education for the prevention of falls in hospital: economic evaluation from a randomized controlled trial |
| Q94452927 | Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis |
| Q49894684 | Cost-effectiveness analyses of genetic and genomic diagnostic tests |
| Q37087365 | Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches |
| Q49963032 | Cost-effectiveness analysis of a school-based dental caries prevention program using fluoridated milk in Bangkok, Thailand |
| Q58761662 | Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico |
| Q41987440 | Cost-effectiveness of diagnostic-therapeutic strategies for paediatric visceral leishmaniasis in Morocco. |
| Q86477564 | Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model |
| Q37323042 | Cost-effectiveness of sentinel lymph node biopsy vs inguinofemoral lymphadenectomy in women with vulval cancer |
| Q41187128 | Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. |
| Q30653195 | Data-driven Markov models and their application in the evaluation of adverse events in radiotherapy |
| Q59808171 | Decision modelling for economic evaluation of liver transplantation |
| Q34077174 | Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. |
| Q55222217 | Discrete Event Simulation for Decision Modeling in Health Care: Lessons from Abdominal Aortic Aneurysm Screening. |
| Q38767961 | Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics |
| Q38366545 | Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies |
| Q34539001 | Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting |
| Q30376306 | Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. |
| Q95642127 | Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma |
| Q40160990 | Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis |
| Q34567701 | Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts |
| Q38010473 | Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models |
| Q37768238 | Economic evaluation, human immunodeficiency virus infection and screening: a review and critical appraisal of economic studies |
| Q38755073 | Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases |
| Q36356288 | Estimating cost-effectiveness in public health: a summary of modelling and valuation methods |
| Q48188462 | Exploring model uncertainty in economic evaluation of health interventions: the example of rotavirus vaccination in Vietnam |
| Q34447408 | Future impact of various interventions on the burden of COPD in Canada: a dynamic population model |
| Q28084540 | Health economic evaluations of visceral leishmaniasis treatments: a systematic review |
| Q36579746 | Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach. |
| Q38171360 | Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models. |
| Q40531883 | Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models: A Case Study in Type 1 Diabetes |
| Q33448660 | Indirect estimation of a discrete-state discrete-time model using secondary data analysis of regression data |
| Q34691029 | Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community |
| Q81581696 | Key principles for the improved conduct of health technology assessments for resource allocation decisions |
| Q43495480 | Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model |
| Q38207748 | Markov modeling and discrete event simulation in health care: a systematic comparison |
| Q38482308 | Mathematical Modeling in Tobacco Control Research: Initial Results From a Systematic Review |
| Q39157429 | Methodological and applied concerns surrounding age-related weighting within health economic evaluation |
| Q36615123 | Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community |
| Q30823226 | Methods to construct a step-by-step beginner's guide to decision analytic cost-effectiveness modeling |
| Q52340299 | Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. |
| Q30382889 | Mitigation of pandemic influenza: review of cost-effectiveness studies. |
| Q50016199 | Model Registration: A Call to Action |
| Q57175289 | Model Structuring for Economic Evaluations of New Health Technologies |
| Q47117818 | Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review. |
| Q38228728 | Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility |
| Q57589510 | Modeling Using Discrete Event Simulation |
| Q38044578 | Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. |
| Q90023140 | Modeling of Diabetes and Its Clinical Impact |
| Q55252091 | Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. |
| Q81626682 | Modelling approaches: the case of schizophrenia |
| Q57193584 | Modelling in Public Health |
| Q37058447 | Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide |
| Q57759101 | Modelling the complete continuum of care using system dynamics: the case of osteoarthritis in Alberta |
| Q37866752 | Modelling the epidemiology of infectious diseases for decision analysis: a primer |
| Q59297509 | Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA |
| Q28597031 | More frequent, more costly? Health economic modelling aspects of monitoring glaucoma patients in England |
| Q39352133 | Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. |
| Q51340958 | Multiple tests of cost-effectiveness angles. |
| Q34719713 | NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? |
| Q30419928 | New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses |
| Q91689068 | Nonidentifiability in Model Calibration and Implications for Medical Decision Making |
| Q91971259 | Optimizing Resources for Endovascular Clot Retrieval for Acute Ischemic Stroke, a Discrete Event Simulation |
| Q30419690 | Planning influenza vaccination programs: a cost benefit model |
| Q64931893 | Population- versus cohort-based modelling approaches. |
| Q41960374 | Reducing access times for an endoscopy department by an iterative combination of computer simulation and linear programming |
| Q38854126 | Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis |
| Q47160345 | Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis |
| Q39640964 | Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations |
| Q40038306 | Resource planning for ambulance services in mass casualty incidents: a DES-based policy model. |
| Q92043581 | Risk factors in the illness-death model: Simulation study and the partial differential equation about incidence and prevalence |
| Q41151369 | Screening for breast cancer with Breast-CT in a ProHTA simulation |
| Q58566948 | Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation |
| Q36385780 | Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews |
| Q88599535 | Smoking Cessation: A Comparison of Two Model Structures |
| Q50100257 | Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care |
| Q61756880 | Structural Sensitivity in HIV Modeling: A Case Study of Vaccination |
| Q34070852 | Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children |
| Q35948458 | Study protocol of SWEPIS a Swedish multicentre register based randomised controlled trial to compare induction of labour at 41 completed gestational weeks versus expectant management and induction at 42 completed gestational weeks |
| Q38743343 | Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease |
| Q35665481 | Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations |
| Q38826997 | Systematic review and overview of health economic evaluation models in obesity prevention and therapy |
| Q90272450 | Targeting TB or MRSA in Norwegian municipalities during 'the refugee crisis' of 2015: a framework for priority setting in screening |
| Q39712672 | The Sheffield rheumatoid arthritis health economic model |
| Q38597139 | The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal. |
| Q89098076 | The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke |
| Q55217201 | The economic case for precision medicine. |
| Q38732124 | The organisational value of diagnostic strategies using high-sensitivity troponin for patients with possible acute coronary syndromes: a trial-based cost-effectiveness analysis. |
| Q37891050 | The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal. |
| Q36169901 | To screen or not to screen for breast cancer? How do modelling studies answer the question? |
| Q57697360 | Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions |
| Q58701365 | Uncertainty Analysis in Population-Based Disease Microsimulation Models |
| Q56333381 | Uncertainty, Probabilistic Analysis and Outputs from Cost Effectiveness Analyses |
| Q35528766 | Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus |
| Q36827936 | Use of a decision-analytic model in a health technology assessment: beyond measuring value for money |
| Q38393698 | Use of value of information in UK health technology assessments |
| Q38739881 | Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling |
| Q37050979 | Using common random numbers in health care cost-effectiveness simulation modeling |
| Q36354798 | Using predictions from a joint model for longitudinal and survival data to inform the optimal time of intervention in an abdominal aortic aneurysm screening programme |
| Q41591206 | Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention |
| Q26741867 | Vaccine epidemiology: A review |
| Q40138081 | Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code |
| Q51667850 | What happens to value of information measures as the number of decision options increases? |
| Q83957945 | [Economic concepts for measuring the costs of illness of osteoporosis: an international comparison] |